Basilea Pharmaceutica erhält Meilensteinzahlung für Cresemba-Verkäufe in Asien und China

Pfizer Inc. -0.81%

Pfizer Inc.

PFE

28.32

-0.81%

Basilea Pharmaceutica AG hat mitgeteilt, dass die anhaltend starken Umsätze des Antimykotikums Cresemba (Isavuconazol) durch den Lizenzpartner Pfizer im asiatisch-pazifischen Raum und in China eine Meilensteinzahlung in Höhe von 5 Millionen US-Dollar ausgelöst haben. Die globalen In-Market-Umsätze von Cresemba beliefen sich im Zeitraum Oktober 2024 bis September 2025 auf 693 Millionen US-Dollar, was einem Wachstum von 27 Prozent im Jahresvergleich entspricht. Cresemba ist in mehr als 75 Ländern erhältlich.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Basilea Pharmaceutica AG published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 1001163604) on February 09, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.